荣昌生物
(688331)
| 流通市值：64.02亿 | | | 总市值：215.17亿 |
| 流通股本：1.62亿 | | | 总股本：5.44亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 664,964,952 | 676,124,693.28 | 622,789,439.47 | 743,392,716.82 |
| 应收票据及应收账款 | 482,106,303.7 | 437,571,784.17 | 407,083,914.32 | 376,373,283.88 |
| 其中：应收票据 | 147,677,318.74 | 129,647,429.43 | 110,706,722.42 | 78,695,674.95 |
| 应收账款 | 334,428,984.96 | 307,924,354.74 | 296,377,191.9 | 297,677,608.93 |
| 应收款项融资 | 51,264,381.26 | 103,052,899.78 | 61,693,042.71 | 44,044,931.02 |
| 预付款项 | 287,105,369.05 | 300,231,183.16 | 291,290,257.15 | 270,294,849.12 |
| 其他应收款合计 | 29,200,438.94 | 30,732,282.72 | 49,435,238.53 | 29,011,543.89 |
| 存货 | 745,387,541.34 | 740,650,308.64 | 751,473,242.66 | 741,559,576.19 |
| 其他流动资产 | 3,798,780.51 | 5,278,443.85 | 18,403,477.85 | 24,255,054.24 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,524,007,322.36 | 2,493,879,928.93 | 2,202,168,612.69 | 2,228,931,955.16 |
| 非流动资产: | | | | |
| 长期股权投资 | 8,850,545.83 | 8,850,355.36 | 9,000,788.49 | 2,705,448.2 |
| 其他权益工具投资 | 53,840,867.96 | 63,482,114.8 | 68,486,996.52 | 93,521,672.55 |
| 其他非流动金融资产 | 3,038,731.56 | 2,856,774.32 | 1,950,535.39 | 2,000,000 |
| 固定资产 | 2,412,993,585.31 | 2,402,126,744.68 | 2,195,752,559.07 | 2,031,305,563.72 |
| 在建工程 | 309,112,443.03 | 376,667,551.29 | 623,143,112.34 | 795,718,495.54 |
| 使用权资产 | 108,139,896.18 | 124,816,666.64 | 123,292,317.05 | 132,248,412.02 |
| 无形资产 | 142,680,567.46 | 144,062,633.49 | 144,875,167.66 | 143,781,479.65 |
| 长期待摊费用 | 5,493,772.56 | 6,478,814.32 | 6,701,387.06 | 6,833,576.52 |
| 其他非流动资产 | 144,555,680.75 | 131,317,462.94 | 103,285,416.55 | 91,194,101.23 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,188,706,090.64 | 3,260,659,117.84 | 3,276,488,280.13 | 3,299,308,749.43 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,712,713,413 | 5,754,539,046.77 | 5,478,656,892.82 | 5,528,240,704.59 |
| 流动负债: | | | | |
| 短期借款 | 1,026,766,746.38 | 930,162,423.13 | 574,000,648.97 | 284,276,638.87 |
| 应付票据及应付账款 | 184,834,362.99 | 133,158,441.74 | 125,408,470.48 | 139,330,943.32 |
| 其中：应付票据 | - | - | - | 13,994,347.44 |
| 应付账款 | 184,834,362.99 | 133,158,441.74 | 125,408,470.48 | 125,336,595.88 |
| 合同负债 | 3,220,361.43 | 3,911,974.33 | 9,833,198.56 | 11,398,410.09 |
| 应付职工薪酬 | 199,275,853.26 | 192,534,656.39 | 180,021,573.9 | 194,940,951.34 |
| 应交税费 | 40,837,332.71 | 12,945,103.5 | 10,605,606.48 | 34,694,547.74 |
| 其他应付款合计 | 272,540,452.82 | 288,194,056.63 | 310,520,251.58 | 391,160,258.67 |
| 一年内到期的非流动负债 | 118,158,847.27 | 65,717,044.34 | 59,283,276 | 60,443,433.9 |
| 其他流动负债 | 15,154,007.15 | 12,097,042.02 | 12,929,940.25 | 11,877,366.49 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 1,860,787,964.01 | 1,638,720,742.08 | 1,282,602,966.22 | 1,128,122,550.42 |
| 非流动负债: | | | | |
| 长期借款 | 1,341,279,937.63 | 1,341,637,543.48 | 1,003,365,763.39 | 840,588,019.63 |
| 租赁负债 | 46,536,564.21 | 60,575,398.53 | 64,398,237.87 | 74,675,060.11 |
| 递延收益 | 95,428,408.34 | 48,995,823.89 | 49,737,729.6 | 46,075,693.04 |
| 递延所得税负债 | - | - | - | 1,511,227.5 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 1,483,244,910.18 | 1,451,208,765.9 | 1,117,501,730.86 | 962,850,000.28 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 3,344,032,874.19 | 3,089,929,507.98 | 2,400,104,697.08 | 2,090,972,550.7 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 544,332,083 | 544,332,083 | 544,332,083 | 544,263,003 |
| 资本公积 | 6,287,590,554.06 | 6,269,443,456.91 | 6,251,640,596.24 | 6,237,868,188.53 |
| 减:库存股 | 444,896,381.34 | 438,160,075.98 | 440,663,441.59 | 440,310,281.32 |
| 其他综合收益 | -93,408,689.99 | -77,035,769.43 | -74,324,957.4 | -51,042,368.3 |
| 未分配利润 | -3,924,937,026.92 | -3,633,970,155.71 | -3,202,432,084.51 | -2,853,510,388.02 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,368,680,538.81 | 2,664,609,538.79 | 3,078,552,195.74 | 3,437,268,153.89 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,368,680,538.81 | 2,664,609,538.79 | 3,078,552,195.74 | 3,437,268,153.89 |
| 负债和股东权益合计 | 5,712,713,413 | 5,754,539,046.77 | 5,478,656,892.82 | 5,528,240,704.59 |
| 公告日期 | 2024-10-30 | 2024-08-17 | 2024-04-27 | 2024-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |